February 15, 2017
Some innovations that we can’t imagine life without today
We owe a lot to pharmaceutical companies for providing us with life saving drugs and a lot of other inventions that make our life easier.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
February 14, 2017
Bomb kills 13, injures 85 during a pharmaceutical related protest in Lahore, Pakistan
At least 13 people were killed and 85 injured when a suicide bomber struck Monday evening around 6pm outside the Punjab Assembly in Lahore during a protest, reported Pakistani Dawn citing police officials.
February 14, 2017
Moberg Pharma increases full year net profit
Moberg Pharma has posted net profit after tax of SEK 32.7 million (€3.45 million) which is up from SEK 25.5 million last year.
February 14, 2017
Probi appoints Jörn Andreas as CFO
Probi AB has appointed Jörn Andreas as CFO. Andreas will replace Niklas Brandt who will remain in Probis leadership team as CIO with responsibility for IT infrastructure and Investor relations.
February 14, 2017
Global biosimilars market could see high double digit growth by 2022.
The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry.
February 14, 2017
Turbulent times for Teva, interim CEO focuses on enhancing value
Turbulent several months for Teva in which it saw many challenges and achievements saw the company loosing its CEO, several trials in the USA, one of which being for bribery, and patent related trials that Teva filed, and was filed against.
February 14, 2017
Chi-Med kicks off human testing of its anti-tumor inhibitor
Hutchison China MediTech Limited (Chi-Med) has kicked off today in Australia the first-in-human (FIH) Phase I clinical testing of inhibitor HMPL-453, for fibroblast growth factor receptor signaling pathway, which forces tumor growth.
February 14, 2017
ViiV Healthcare studies on treating HIV with two drug regimen
ViiV Healthcare, majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, has announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC).
February 14, 2017
Update: Horizon Discovery expands deal with its largest single customer
Horizon Discovery Group has sign a Master Services Agreement with its largest customer, which will be a template for increasing revenue for about £2 million in 2017.
February 14, 2017
European Commission approves Lilly’s and Incyte’s rheumatoid arthritis drug
Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).